Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at ERS Annual Congress

Pulmatrix, Inc.Aug 28 2012

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM™ therapeutic, the first treatment developed utilizing its iSPERSE™ inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.

The results presented in these posters will encompass clinical and preclinical data that highlight the potential of the company's drug candidates for respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis (CF). The schedule and details of the presentations are as follows:

• Monday, September 3, 2012. Poster viewing 12:50-14:40 CET (6:50-8:50 am ET): iCALM inhaled cationic salts modulate macrophage function to reduce inflammation during LPS induced lung injury. Session 246 -- Thematic Poster Session: Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD. Location: Halle A-8.
• Monday, September 3, 2012. Poster viewing 12:50-14:40 CET (6:50-8:50 am ET): iCALM inhaled calcium salts reduce expression of inflammatory mediators - in tobacco smoke exposure models to demonstrate reduced airway inflammation. Session 246 -- Thematic Poster Session: Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD. Location: Halle A-8.
• Monday, September 3, 2012. Poster viewing 12:50-14:40 CET (6:50-8:50 am ET): Design and implementation of a multi-part, flexible clinical trial protocol to assess the tolerability and pharmacodynamic effects of PUR118 in healthy subjects and COPD patients. Poster co-authored by Quotient Clinical and Pulmatrix. Session 247 -- Thematic Poster Session: The best of pharmacology treatments of airway diseases: new devices and drugs. Location: Halle A-9.